{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:47:05Z","timestamp":1786992425470,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jfma.2024.01.007","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T16:08:17Z","timestamp":1704816497000},"page":"802-810","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Monocentric study of IL-5 monoclonal antibody induction therapy for eosinophilic granulomatosis with polyangiitis"],"prefix":"10.1016","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9881-7024","authenticated-orcid":false,"given":"Chrong-Reen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9223-2535","authenticated-orcid":false,"given":"Hung-Wen","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chang","family":"Shieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2024.01.007_bib1","first-page":"277","article-title":"Allergic granulomatosis, allergic angiitis, and periarteritis","volume":"27","author":"Churg","year":"1951","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jfma.2024.01.007_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103219","article-title":"Eosinophilic granulomatosis with polyangiitis: a review","volume":"22","author":"White","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jfma.2024.01.007_bib3","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41584-023-00958-w","article-title":"Evidence-Based guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis","volume":"19","author":"Emmi","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jfma.2024.01.007_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"Revised international Chapel Hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jfma.2024.01.007_bib5","doi-asserted-by":"crossref","first-page":"iii84","DOI":"10.1093\/rheumatology\/kez570","article-title":"Eosinophilic granulomatosis with polyangiitis: understanding the disease and its management","volume":"59","author":"Trivioli","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.jfma.2024.01.007_bib6","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.jaci.2012.07.024","article-title":"Workshop report from the national institutes of health taskforce on the research needs of eosinophil-associated diseases (TREAD)","volume":"130","author":"Bochner","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jfma.2024.01.007_bib7","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nrrheum.2014.98","article-title":"Eosinophils in vasculitis: characteristics and roles in pathogenesis","volume":"10","author":"Khoury","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jfma.2024.01.007_bib8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","article-title":"The Five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort","volume":"90","author":"Guillevin","year":"2011","journal-title":"Medicine"},{"key":"10.1016\/j.jfma.2024.01.007_bib9","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.jaip.2018.07.001","article-title":"Eosinophilic granulomatosis with polyangiitis: clinical pathology conference and review","volume":"6","author":"Wu","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jfma.2024.01.007_bib10","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3389\/fimmu.2014.00549","article-title":"Eosinophilic granulomatosis with polyangiitis: an overview","volume":"5","author":"Gioffredi","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.jfma.2024.01.007_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2022.100676","article-title":"Current and emerging biologic therapies targeting eosinophilic disorders","volume":"15","author":"Pitlick","year":"2022","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jfma.2024.01.007_bib12","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1136\/ard-2022-223044","article-title":"Targeting the interleukin-5 pathway in EGPA: evidence, uncertainties and opportunities","volume":"82","author":"Berti","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jfma.2024.01.007_bib13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12325-022-02307-x","article-title":"A review of anti-IL-5 therapies for eosinophilic granulomatosis with polyangiitis","volume":"40","author":"Koike","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.jfma.2024.01.007_bib14","article-title":"Switching from omalizumab to mepolizumab therapy improved extra-pulmonary abdominal and cutaneous vasculitis symptoms in a patient with eosinophilic granulomatosis with polyangiitis","volume":"10","author":"Chen","year":"2021","journal-title":"Respirol Case Rep"},{"key":"10.1016\/j.jfma.2024.01.007_bib15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.46497\/ArchRheumatol.2023.9559","article-title":"Mepolizumab therapy improves endomyocarditis in seropositive eosinophilic granulomatosis with polyangiitis","volume":"38","author":"Wang","year":"2023","journal-title":"Arch Rheumatol"},{"key":"10.1016\/j.jfma.2024.01.007_bib16","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.jfma.2023.05.036","article-title":"Remission of refractory eosinophilic gastrointestinal disease in an eosinophilic granulomatosis with polyangiitis patient by anti-IL-5 therapy","volume":"122","author":"Wang","year":"2023","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2024.01.007_bib17","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/art.1780330806","article-title":"The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis)","volume":"33","author":"Masi","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jfma.2024.01.007_bib18","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the Birmingham vasculitis activity score (version 3)","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jfma.2024.01.007_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102618","article-title":"International consensus on ANCA testing beyond systemic vasculitis","volume":"19","author":"Moiseev","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jfma.2024.01.007_bib20","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/annrheumdis-2014-206095","article-title":"Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","volume":"75","author":"Mohammad","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jfma.2024.01.007_bib21","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.3390\/jcm10194577","article-title":"B-cell-depleting therapy improves myocarditis in seronegative eosinophilic granulomatosis with polyangiitis","volume":"10","author":"Wang","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.jfma.2024.01.007_bib22","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/PL00011209","article-title":"Multiple colonic ulcers caused by Churge-Strauss syndrome in a 15-year-old girl","volume":"20","author":"Lin","year":"2001","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jfma.2024.01.007_bib23","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.3899\/jrheum.171352","article-title":"Longterm outcomes of 188 Japanese patients with eosinophilic granulomatosis with polyangiitis","volume":"45","author":"Saku","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jfma.2024.01.007_bib24","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1093\/rheumatology\/keaa805","article-title":"Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","volume":"60","author":"Papo","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.jfma.2024.01.007_bib25","article-title":"Clinical significance of MPO-ANCA in eosinophilic granulomatosis with polyangiitis: Experience from a longitudinal Chinese cohort","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jfma.2024.01.007_bib26","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12929-022-00849-4","article-title":"Down-regulated miR-146a expression with increased neutrophil extracellular traps and apoptosis formation in autoimmune-mediated diffuse alveolar hemorrhage","volume":"29","author":"Hsieh","year":"2022","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.jfma.2024.01.007_bib27","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12929-023-00969-5","article-title":"Long noncoding RNA SNHG16 regulates TLR4-mediated autophagy and NETosis formation in alveolar hemorrhage associated with systemic lupus erythematosus","volume":"30","author":"Hsieh","year":"2023","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.jfma.2024.01.007_bib28","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"American College of Rheumatology\/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jfma.2024.01.007_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jfma.2023.10.024","article-title":"High occurrence of autoimmune and lymphoproliferative manifestations in adults with common variable immunodeficiency in southern Taiwan","author":"Wang","year":"2023","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2024.01.007_bib30","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S1081-1206(10)61714-0","article-title":"Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin","volume":"92","author":"Tsurikisawa","year":"2004","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jfma.2024.01.007_bib31","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1146\/annurev.immunol.24.021605.090720","article-title":"The eosinophil","volume":"24","author":"Rothenberg","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jfma.2024.01.007_bib32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.alit.2020.09.002","article-title":"Eosinophils: cells known for over 140 years with broad and new functions","volume":"70","author":"Aoki","year":"2021","journal-title":"Allergol Int"},{"key":"10.1016\/j.jfma.2024.01.007_bib33","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/intimm\/dxp102","article-title":"IL-5- and eosinophil-mediated inflammation: from discovery to therapy","volume":"21","author":"Kouro","year":"2009","journal-title":"Int Immunol"},{"key":"10.1016\/j.jfma.2024.01.007_bib34","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1136\/ard-2022-223044","article-title":"Targeting the interleukin-5 pathway in EGPA: evidence, uncertainties and opportunities","volume":"82","author":"Berti","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jfma.2024.01.007_bib35","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.rdc.2023.03.006","article-title":"Therapeutic advances in eosinophilic granulomatosis with polyangiitis","volume":"49","author":"Bloom","year":"2023","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jfma.2024.01.007_bib36","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2024.01.007_bib37","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12931-021-01775-z","article-title":"Real-life evidence of low-dose mepolizumab efficacy in EGPA: a case series","volume":"22","author":"Detoraki","year":"2021","journal-title":"Respir Res"},{"key":"10.1016\/j.jfma.2024.01.007_bib38","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1016\/j.jaip.2021.03.061","article-title":"Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis in remission: what is the right dose?","volume":"9","author":"Akdime","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jfma.2024.01.007_bib39","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/art.41943","article-title":"Mepolizumab for eosinophilic granulomatosis with polyangiitis: a European multicenter observational study","volume":"74","author":"Bettiol","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jfma.2024.01.007_bib40","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1136\/annrheumdis-2020-219498","article-title":"Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"80","author":"Strangfeld","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jfma.2024.01.007_bib41","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1177\/10600280221129823","article-title":"Fatal COVID-19 pneumonia in a rheumatoid arthritis patient receiving long-term rituximab therapy","volume":"57","author":"Wang","year":"2022","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jfma.2024.01.007_bib42","article-title":"Onset or flare of systemic lupus erythematosus preceded by severe acute respiratory syndrome coronavirus 2 infection","author":"Wang","year":"2023","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2024.01.007_bib43","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jfma.2023.04.023","article-title":"Viral dynamics of SARS-CoV-2 Omicron infections in a previously low COVID-19 prevalence region: effects of vaccination status, antiviral agents, and age","volume":"122","author":"Chang","year":"2023","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2024.01.007_bib44","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jfma.2023.03.002","article-title":"Severe COVID-19 pneumonia in patients with rheumatoid arthritis under B-cell depletion therapy","volume":"122","author":"Wang","year":"2023","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2024.01.007_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.622554","article-title":"Anti-IL5 drugs in COVID-19 patients: role of eosinophils in SARS-CoV-2-induced immunopathology","volume":"12","author":"Pala","year":"2021","journal-title":"Front Pharmacol"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664624000263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664624000263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T19:32:08Z","timestamp":1719430328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664624000263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0929664624000263"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2024.01.007","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monocentric study of IL-5 monoclonal antibody induction therapy for eosinophilic granulomatosis with polyangiitis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2024.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}